CD4 and B-cell non-Hodgkin lymphoma: Previous studies have reported that high levels of CD4+ T cells are associated with improved survival outcomes in many malignancies [31], and mouse models of B–cell lymphoma suggest that CD4+ T cells are key to the establishment of an antitumor microenvironment [32].